ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

(2015) M. Kwok et al.   BLOOD

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997

(2015) David M. Lucas et al.   LEUKEMIA & LYMPHOMA

ATM: Expanding roles as a chief guardian of genome stability

(2014) Yosef Shiloh   EXPERIMENTAL CELL RESEARCH

MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping

(2014) Wan-Ping Lee et al.   PLoS One

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin

(2013) V. Navrkalova et al.   HAEMATOLOGICA

The role ofATMmutations and 11q deletions in disease progression in chronic lymphocytic leukemia

(2013) Tatjana Stankovic et al.   LEUKEMIA & LYMPHOMA

Overview of available p53 function tests in relation toTP53andATMgene alterations and chemoresistance in chronic lymphocytic leukemia

(2013) G. Doreen te Raa et al.   LEUKEMIA & LYMPHOMA

MicroRNA-18a Attenuates DNA Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated in Colorectal Cancer

(2013) Chung-Wah Wu et al.   PLoS One

Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors

(2013) A. Riabinska et al.   Science Translational Medicine

Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia

(2012) Peter Ouillette et al.   GENES CHROMOSOMES & CANCER

Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial

(2012) Anna Skowronska et al.   JOURNAL OF CLINICAL ONCOLOGY

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

(2012) Gerard Lozanski et al.   LEUKEMIA & LYMPHOMA

BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation

(2012) S Shabbeer et al.   ONCOGENE

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

(2011) A. Guarini et al.   HAEMATOLOGICA

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele

(2011) A. Skowronska et al.   HAEMATOLOGICA

No evidence for DNA methylation of theATMpromoter CpG island in chronic lymphocytic leukemia

(2011) Thomas Mikeska et al.   LEUKEMIA & LYMPHOMA

miR-18a Impairs DNA Damage Response through Downregulation of Ataxia Telangiectasia Mutated (ATM) Kinase

(2011) Libing Song et al.   PLoS One

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

(2010) V. J. Weston et al.   BLOOD

ATM is down-regulated by N-Myc-regulated microRNA-421

(2010) H. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

(2009) L. S. Chen et al.   BLOOD

Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia

(2009) S R Gunn et al.   LEUKEMIA

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

(2008) O G Best et al.   LEUKEMIA